Commercialising Direct-to-Consumer Genomics
In 2007, 23andMe launched its direct-to-consumer (DTC) genetic testing service, introducing a novel business model in personal genomics. Customers could purchase a kit, submit a saliva sample, and receive a report outlining ancestry composition, selected traits, and preliminary health insights. This model initially relied on a one-time payment, with no recurring charges.
The concept gained rapid traction. Public interest in ancestry surged, and the accessibility of genetic information became a cultural phenomenon. By 2012, the term "spit kit" was widely recognised, and 23andMe had positioned itself as a pioneer in the growing field of consumer genomics.
Despite its popularity, 23andMe encountered regulatory challenges. In 2013, the U.S. Food and Drug Administration (FDA) mandated that the company cease offering health-related interpretations until it could demonstrate analytical and clinical validity. The company subsequently suspended these features for two years whilst undergoing regulatory review.
When health reporting resumed in 2015, the product was restructured. The company introduced tiered pricing, offering basic ancestry services with optional health features at an added cost. Nevertheless, the one-time payment structure persisted, and the absence of recurring engagement with users remained a significant limitation to long-term revenue.
Market Pressures and the Transition to Public Ownership
As initial user growth plateaued, venture capital backers began seeking liquidity. In 2021, 23andMe completed a merger with VG Acquisition Corp., a special-purpose acquisition company (SPAC), thereby becoming publicly listed under the ticker symbol ME. The transaction valued the company at approximately $3.5 billion.
Going public altered the strategic focus. Quarterly financial disclosures replaced internal reports, and profit maximisation for shareholders became a legal obligation. The direct-to-consumer model, with limited opportunities for upselling or customer retention, came under scrutiny.
To respond to these pressures, 23andMe introduced several initiatives:
- Subscription Services — The company launched 23andMe+, a membership programme offering extended insights and periodic updates for an annual fee.
- Data Licensing Partnerships — Collaborations with pharmaceutical firms, notably GlaxoSmithKline, enabled the monetisation of aggregated genomic data for research and drug development.
- Consumer Health Products — The company briefly offered genomics-themed skincare and wellness supplements, although these received limited scientific validation and consumer uptake.
Whilst theoretically promising, these efforts yielded mixed results. Subscription adoption plateaued, business-to-business income was uneven, and consumer products did not scale.
Data Security Incident and Public Confidence
On 1 October 2023, 23andMe suffered a significant data breach involving a credential-stuffing attack. Malicious actors gained access to user accounts and extracted relationship data from the DNA Relatives and family tree features. Although raw genetic data was not compromised, the incident revealed personal information such as names and genetic relationships.
This breach further eroded public trust and amplified privacy concerns. Legal actions in multiple jurisdictions soon followed.
On 23 March 2025, 23andMe filed for Chapter 11 bankruptcy protection in the Eastern District of Missouri. Court documents revealed liabilities totalling approximately $1 billion and cash reserves of $50 million.
On 19 May 2025, Regeneron Pharmaceuticals was announced as the winning bidder, offering about $256 million for most of the company's assets. The sale did not end there. The court reopened the auction in June, and on 13 June 2025, 23andMe named a new winner: TTAM Research Institute, a nonprofit public benefit corporation founded by 23andMe co-founder and former CEO Anne Wojcicki, with a bid of $305 million. Earlier that month, 27 states and the District of Columbia had sued to require customer consent before genetic data changes hands. The bankruptcy court approved the sale on 27 June 2025, and the acquisition closed on 14 July 2025.
Under TTAM, 23andMe keeps operating under the same name. TTAM committed to honour the existing privacy policy, to preserve customers' right to delete their data and to withdraw from research, and to notify customers of the change of ownership. The practical lesson did not change: the only controls over your genetic data that you can count on are the ones you exercise yourself.
The Enduring Value of Raw Genomic Data
Consumers who submitted DNA samples to 23andMe were granted access to their raw data, specifically single-nucleotide polymorphism (SNP) files. These files, typically around 25 megabytes in size, list hundreds of thousands of loci along with the individual's corresponding genotype.
These raw files are valuable beyond the original reports. Various third-party tools and platforms can be used to analyse them:
- GEDmatch enables cross-platform matching for genealogy research
- DNA Painter maps inheritance patterns across chromosomes
- Promethease offers literature-based variant interpretations
- Full-Human.Health provides health and wellness reports using genomic input
Our approach emphasises personal empowerment: everyone should have access to their own genomic data, along with open tools to understand it. We do not store user genomes unless there is clear, informed approval. The default is privacy-first, with analysis performed client-side or temporarily in secure environments without long-term retention.
Given the irreversible nature of genetic deletion, users are strongly encouraged to download and securely archive their data prior to initiating any account closure.
What to Do Now: Download, Secure, Delete
Whether you stay with 23andMe under TTAM or leave, the same four steps protect you. Raw-data downloads still work at the time of writing (October 2026).
- Download your raw data. In your 23andMe account, open Settings, then 23andMe Data, and request the raw data download. Confirm that the file opens and is complete before you do anything else.
- Store it securely. Keep the file in encrypted storage with a second copy in a separate location.
- Ask for your sample to be destroyed. Under Settings, in Preferences, you can request destruction of your stored saliva sample. Laboratory confirmation can take several weeks.
- Delete the account if you are leaving. Settings, then 23andMe Data, offers permanent deletion. 23andMe states that data is removed from active systems within 30 days, with some records kept where the law requires it. You can also withdraw research consent without deleting the account.
The claims window for customers affected by the 2023 data breach closed on 14 July 2025.
The bankruptcy of 23andMe signals deeper questions about the sustainability of DTC genomics under current business models. Legislative proposals in the U.S. and the EU are considering stricter privacy protections and transparency in algorithmic decision-making.
Emerging competitors are exploring alternative approaches:
- EncrypGen uses decentralised platforms to allow users to licence their genomic data selectively
- Nebula Genomics emphasises full genome sequencing and end-to-end encryption
- Clinical integrators offer sequencing coupled with in-person genetic counselling
- Full-Human.Health promotes data ownership and privacy, with users retaining full control of their raw genetic data
These models seek to balance innovation with individual autonomy and ethical stewardship of sensitive information.
Despite corporate instability, DNA persists as a biological constant. It transcends companies, markets, and technological cycles. A properly stored genome file remains a useful asset, enabling future analysis, health insights, and genealogical discovery.
As commercial genomics matures, consumers and regulators alike will need to demand transparency, privacy, and long-term control over personal data. The fate of 23andMe is both a cautionary tale and a transitional chapter in the evolving relationship between individuals and their biological information.
This article is intended for informational purposes and does not constitute legal or medical advice.
This article is for general information only and is not medical advice. Talk to a qualified healthcare professional before making health decisions based on genetic data.
Ready to explore your own DNA?
Turn your raw DNA file into a clear health report
Full Human processes compatible DNA files privately in your browser and creates a downloadable PDF with links to scientific literature.
Your DNA file stays on your device during report generation.